francesca’s® Updates and Reaffirms Fourth Quarter 2016 Guidance Based on Holiday Results
Jan 09, 2017 12:30 pm UTC| Business
HOUSTON, Jan. 09, 2017 -- Francesca’s Holdings Corporation (NASDAQ:FRAN) today announced that the Company has updated and reaffirmed its guidance for the fourth quarter ending January 28, 2017 based on its holiday...
The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
Jan 09, 2017 12:08 pm UTC| Business
Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for use in the treatment of...
Cutera Names James A. Reinstein as its Next President and CEO
Jan 09, 2017 12:01 pm UTC| Business
BRISBANE, Calif., Jan. 09, 2017 -- Cutera, Inc. (NASDAQ:CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced the appointment of James...
uniQure Outlines Key Initiatives for 2017 and Vision for 2018
Jan 09, 2017 12:01 pm UTC| Business
-- Preparations Underway for Late-Stage Development in Hemophilia B -- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies-- Company Strengthened Following Strategic Review and New...
Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program
Jan 09, 2017 12:01 pm UTC| Business
- Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission- Top-line results from the MEASURE study to be reported in the coming weeks- FDA to modify Clinical Hold from...
Jan 09, 2017 12:01 pm UTC| Business
BRISBANE, Calif., Jan. 09, 2017 -- Cutera, Inc. (NASDAQ:CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced the following...
VBL Therapeutics Provides Year End 2016 Corporate Update
Jan 09, 2017 12:01 pm UTC| Business
TEL AVIV, Israel, Jan. 09, 2017 -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017. Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to...